Welcome to our dedicated page for Milestone Scient news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scient stock.
Milestone Scient (MLSS) delivers innovative computer-controlled anesthetic systems designed to improve patient comfort in dental and medical procedures. This dedicated news hub provides real-time updates on the company’s technological advancements, regulatory milestones, and strategic partnerships.
Access authoritative information on MLSS’s global expansion across 25+ countries, product innovations like the CompuDent and CompuMed systems, and financial performance. The curated content serves investors and healthcare professionals seeking to monitor the company’s impact on pain management technology.
Key updates include FDA clearances, clinical trial results, partnership announcements with medical institutions, and market penetration strategies. All content is sourced directly from official company communications to ensure accuracy and timeliness.
Bookmark this page for streamlined access to MLSS’s latest developments, enabling data-driven insights into its role in advancing precision anesthetic delivery worldwide.
Milestone Scientific Inc. (NYSE: MLSS) has announced a strategic partnership with Axial Biologics to distribute its CompuFlo® Epidural System in New Jersey, Texas, and Florida. This follows recent Medicare Part B Physician payment rate approvals for the system under the AMA's Category III CPT® code CPT0777T by Novitas Solutions, Inc. and First Coast Service Options Inc.
The partnership aims to leverage Axial Biologics' extensive experience and relationships in the pain management sector to accelerate the adoption of CompuFlo®. This collaboration represents a focused approach to expand Milestone's reach in key states, potentially driving growth and enhancing patient outcomes.
The CompuFlo® Epidural System is designed to provide precise identification of the epidural space, reducing complications associated with traditional methods. The recent Medicare Price Assignment is expected to facilitate broader adoption across the United States.
Milestone Scientific Inc. (NYSE: MLSS) has received multiple Notices of Allowance for key patent applications in the U.S. and Europe. These patents cover the company's next-generation Dynamic Pressure Sensing® (DPS) technology for real-time pressure-sensing guidance in manual injection systems and the new CompuPulse System for identifying pulsatile pressure waveforms.
The DPS technology enables fluid-pressure analysis to compare pressure signals, alert pressure thresholds, and display pressure graphs, enhancing the safety and precision of manual injections. The CompuPulse System improves the reliability and safety of drug delivery using manual syringes.
CEO Arjan Haverhals stated that these patent approvals significantly broaden the company's intellectual property foundation and reinforce its leadership in the computerized injection market, while opening new avenues for their technology in diverse markets and applications.
Milestone Scientific (NYSE: MLSS) has secured Medicare price assignment for its CompuFlo® Epidural System in 12 states through Novitas Solutions. This covers Medicare regions Jurisdiction L and H, following a recent approval in Florida. The decision applies to the AMA's Category III CPT® code CPT0777T for real-time pressure-sensing epidural guidance systems.
This expansion represents a significant market opportunity, with an estimated 3.0 million epidural steroid injection procedures performed annually in these jurisdictions, accounting for about one-third of total U.S. procedures. The initial addressable market among Medicare patients in these regions is approximately $250 million. The CompuFlo® system uses Dynamic Pressure Sensing® technology to enhance patient safety and outcomes in epidural procedures.
Milestone Scientific announced that its CompuFlo® Epidural System received favorable Medicare pricing from First Coast Service Options (FCSO) in Florida. This marks a critical milestone in Milestone's strategy to enhance coverage and payment for its technology. The decision impacts an estimated $125 million market among Florida Medicare patients. CEO Arjan Haverhals highlighted the strategic and methodical approach to achieving this reimbursement. The FDA-cleared CompuFlo® System uses Dynamic Pressure Sensing® technology to ensure accurate needle placement, enhancing patient safety and comfort. Milestone plans to expand its reimbursement strategy to other Medicare jurisdictions nationwide.
Milestone Scientific has received approval from Brazil's National Health Surveillance Agency (ANVISA) to market its CompuFlo® Epidural System in Brazil. This system uses patented Dynamic Pressure Sensing® technology for accurate, safe, and comfortable epidural needle placement, applicable to lumbar, thoracic, and cervical-thoracic areas. Brazil, being the 9th largest economy, has over 21 million people with chronic back pain and performs an estimated 4-5 million epidural procedures annually. The company has established key relationships with medical institutions and commercial entities in Brazil, expecting to expand the addressable market and improve patient safety and provider experience. This approval follows prior FDA approval in the U.S. and marks a significant step in Milestone's global expansion.
Milestone Scientific (NYSE: MLSS) reported $2.2 million in revenue for Q1 2024, down from $2.6 million in Q1 2023. The company's gross margin increased to 74.5%, up from 72.7%. The increase is attributed to a 31% rise in sales through their new online portal.
However, international revenues fell by $274,000. The company continues to advance its CompuFlo® Epidural System and has submitted over 160 claims for reimbursement. Operating loss for the quarter was $1.5 million, slightly higher than the $1.3 million loss in Q1 2023. Milestone Scientific ended the quarter with $5 million in cash and marketable securities.
Milestone Scientific Inc. (NYSE:MLSS) is set to announce its first-quarter 2024 financial results and business updates on May 16th, 2024. The company specializes in computerized drug delivery instruments for painless and precise injections. The conference call will cover financial performance, corporate progress, and recent developments.
FAQ
What is the current stock price of Milestone Scient (MLSS)?
What is the market cap of Milestone Scient (MLSS)?
